1. Antibiotic resistance threats in the United States 2019 , 2019, http://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
Google Scholar2. Guh, A, Mu, Y, Winston, L, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020; 382: 1320–1330.
Google Scholar | Crossref | Medline3. Rodrigues, R, Barber, G, Ananthakrishnan, A. A comprehensive study of costs associated with recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 2016; 38: 196–202.
Google Scholar | Crossref | Medline4. Olsen, M, Yan, Y, Reske, K, et al. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect 2015; 21: 164–170.
Google Scholar | Crossref | Medline5. Aslam, S, Hamill, R, Musher, D. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5: 549–557.
Google Scholar | Crossref | Medline | ISI6. Ma, GK, Brensinger, CM, Wu, Q, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med 2017; 167: 152–158.
Google Scholar | Crossref | Medline7. McDonald, L, Gerding, D, Johnson, S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66: e1–e48.
Google Scholar | Crossref | Medline8. Wadhwa, A, Al Nahhas, MF, Dierkhising, RA, et al. High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection. Aliment Pharmacol Ther 2016; 44: 576–582.
Google Scholar | Crossref | Medline9. Dayananda, P, Wilcox, MH. Irritable bowel syndrome following Clostridium difficile infection. Curr Opin Gastroenterol 2019; 35: 1–5.
Google Scholar | Crossref | Medline10. Sandhu, A, Tillotson, G, Polistico, J, et al. Clostridioides difficile in COVID-19 patients, Detroit, Michigan, USA, March-April 2020. Emerg Infect Dis 2020; 26: 2272–2274.
Google Scholar | Crossref11. Lakkasani, S, Chan, K, Shaaban, H. Clostridiodes difficile in COVID-19 patients, Detroit, Michigan, USA, March-April 2020. Emerg Infect Dis 2020; 26: 2299–2300.
Google Scholar | Crossref12. Chilton, C, Pickering, D, Freeman, J. Microbiologic factors affecting Clostridium difficile recurrence. Clin Microbiol Infect 2018; 24: 476–482.
Google Scholar | Crossref | Medline13. Khoruts, A, Sadowsky, M. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 2016; 13: 508–516.
Google Scholar | Crossref | Medline14. Liubakka, A, Vaughn, B. Clostridium difficile infection and fecal microbiota transplant. AACN Adv Crit Care 2016; 27: 324–337.
Google Scholar | Crossref | Medline15. Barberio, B, Facchin, S, Mele, E, et al. Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital. Therap Adv Gastroenterol 2020; 13: 1756284820934315.
Google Scholar | SAGE Journals16. Ianiro, G, Murri, R, Sciumè, GD, et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann Intern Med 2019; 171: 695–702.
Google Scholar | Crossref | Medline17. Hocquart, M, Lagier, JC, Cassir, N, et al. Early fecal microbiota transplantation improves survival in severe Clostridium difficile infections. Clin Infect Dis 2018; 66: 645–650.
Google Scholar | Crossref | Medline18. Van Nood, E, Vrieze, A, Nieuwdorp, M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407–415.
Google Scholar | Crossref | Medline | ISI19. Cammarota, G, Masucci, L, Ianiro, G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41: 835–843.
Google Scholar | Crossref | Medline | ISI20. Hota, SS, Sales, V, Tomlinson, G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis 2017; 64: 265–271.
Google Scholar | Crossref | Medline21. Hvas, CL, Dahl Jørgensen, SM, Jørgensen, SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 2019; 156: 1324–1332.e3.
Google Scholar | Crossref22. Baunwall, SMD, Lee, MM, Eriksen, MK, et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. EClinicalMedicine 2020; 29–30: 100642.
Google Scholar23. Youngster, I, Sauk, J, Pindar, C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58: 1515–1522.
Google Scholar | Crossref | Medline | ISI24. Jiang, ZD, Ajami, NJ, Petrosino, JF, et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection – fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther 2017; 45: 899–908.
Google Scholar | Crossref | Medline25. Jiang, ZD, Jenq, RR, Ajami, NJ, et al. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: a randomized clinical trial. PLoS One 2018; 13: e0205064.
Google Scholar | Crossref | Medline26. Lee, CH, Steiner, T, Petrof, EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2016; 315: 142–149.
Google Scholar | Crossref | Medline | ISI27. Kao, D, Roach, B, Silva, M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2017; 318: 1985–1993.
Google Scholar | Crossref | Medline28. Ianiro, G, Maida, M, Burisch, J, et al. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: a systematic review and meta-analysis. United European Gastroenterol J 2018; 6: 1232–1244.
Google Scholar | SAGE Journals | ISI29. Hui, W, Li, T, Liu, W, et al. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: an updated randomized controlled trial meta-analysis. PLoS One 2019; 14: e0210016.
Google Scholar | Crossref | Medline30. Khan, MY, Dirweesh, A, Khurshid, T, et al. Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018; 30: 1309–1317.
Google Scholar | Crossref | Medline31. Moayyedi, P, Yuan, Y, Baharith, H, et al. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust 2017; 207: 166–172.
Google Scholar | Crossref | Medline32. Quraishi, MN, Widlak, M, Bhala, N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 2017; 46: 479–493.
Google Scholar | Crossref | Medline33. Guery, B, Menichetti, F, Anttila, VJ, et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis 2018; 18: 296–307.
Google Scholar | Crossref | Medline34. Navalkele, BD, Polistico, J, Sandhu, A, et al. Clinical outcomes after faecal microbiota transplant by retention enema in both immunocompetent and immunocompromised patients with recurrent Clostridioides difficile infections at an academic medical centre. J Hosp Infect 2020; 106: 643–648.
Google Scholar | Crossref | Medline35. Wilcox, MH, Gerding, DN, Poxton, IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017; 376: 305–317.
Google Scholar | Crossref | Medline36. Basu, A, Prabhu, VS, Dorr, MB, et al. Bezlotoxumab is associated with a reduction in cumulative inpatient-days: analysis of the hospitalization data from the MODIFY I and II clinical trials. Open Forum Infect Dis 2018; 5: ofy218.
Google Scholar | Crossref | Medline37. Prabhu, VS, Cornley, OA, Golan, Y, et al. Thirty day readmissions in hospitalized patients who received bezolotoxumab with antibacterial drug treatment for Clostridium difficile infection. Clin Infect Dis 2017; 65: 1218–1221.
Google Scholar | Crossref | Medline38. Hengel, RL, Ritter, TE, Nathan, RV, et al. Real-world experience of bezlotoxumab for prevention of Clostridioides difficile infection: a retrospective multicenter cohort study. Open Forum Infect Dis 2020; 7: ofaa097.
Google Scholar | Crossref | Medline39. Alhifany, AA, Almutairi, AR, Almangour, TA, et al. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials. BMJ Open 2019; 9: e031145.
Google Scholar | Crossref | Medline40. Kaako, A, Al-Amer, M, Abdeen, Y. Bezlotoxumab use as adjunctive therapy with the third fecal microbiota transplant in refractory recurrent Clostridium difficile colitis; a case report and concise literature review. Anaerobe 2019; 55: 112–116.
Google Scholar | Crossref | Medline41. Kelly, CR, Yen, EF, Grinspan, AM, et al. Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT national registry. Gastroenterology 2021; 160: 183–192.e3.
Google Scholar | Crossref42. Brandt, LJ, Aroniadis, OC, Mellow, M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079–1087.
Google Scholar | Crossref | Medline | ISI43. Li, YT, Cai, HF, Wang, ZH, et al. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther 2016; 43: 445–457.
Google Scholar | Crossref | Medline44. Saha, S, Mara, K, Pardi, DS, et al. Long-term safety of fecal microbiota transplantation for recurrent Clostridioides difficile infection. Gastroenterology 2021; 160: 1961–1969.e3.
Google Scholar | Crossref | Medline45. Drewes, JL, Corona, A, Sanchez, U, et al. Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile. JCI Insight 2019; 4: e130848.
Google Scholar | Crossref | Medline46. Nooij, S, Ducarmon, QR, Laros, JFJ, et al. Fecal microbiota transplantation influences procarcinogenic Escherichia coli in recipient recurrent Clostridioides difficile patients. Gastroenterology 2021; 161: 1218–1228.
Google Scholar | Crossref | Medline47. Bafeta, A, Yavchitz, A, Riveros, C, et al. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med 2017; 167: 34–39.
Google Scholar | Crossref | Medline48. Cammarota, G, Ianiro, G, Kelly, CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 2019; 68: 2111–2121.
Google Scholar